Vivos (OTCMKTS:RDGL) vs. Westaim (OTCMKTS:WEDXF) Financial Survey

Vivos (OTCMKTS:RDGLGet Free Report) and Westaim (OTCMKTS:WEDXFGet Free Report) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Vivos and Westaim, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vivos 0 0 0 0 N/A
Westaim 0 0 0 0 N/A

Volatility and Risk

Vivos has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Westaim has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares Vivos and Westaim’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vivos N/A N/A -201.99%
Westaim 1,323.83% 22.34% 20.94%

Valuation & Earnings

This table compares Vivos and Westaim’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vivos $20,000.00 4,021.90 -$2.89 million ($0.01) -19.25
Westaim $8.63 million 43.96 $183.98 million $0.81 3.65

Westaim has higher revenue and earnings than Vivos. Vivos is trading at a lower price-to-earnings ratio than Westaim, indicating that it is currently the more affordable of the two stocks.

Summary

Westaim beats Vivos on 7 of the 9 factors compared between the two stocks.

About Vivos

(Get Free Report)

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Westaim

(Get Free Report)

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.

Receive News & Ratings for Vivos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos and related companies with MarketBeat.com's FREE daily email newsletter.